NCT00553332View on ClinicalTrials.gov

Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
Liver and Intrahepatic Biliary Tract CancerRecurrent Extrahepatic Bile Duct CancerUnresectable Extrahepatic Bile Duct Cancer
Interventions
DRUG

selumetinib

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (7)

27599

University of North Carolina, Chapel Hill

30322

Emory University, Atlanta

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

37232

Vanderbilt University, Nashville

43210

Ohio State University Medical Center, Columbus

48202

Wayne State University, Detroit

48109-0352

University of Michigan Cancer Center (UMCC) Research Base, Ann Arbor

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00553332 - Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery | Biotech Hunter | Biotech Hunter